Viking Therapeutics, Inc
VKTXNasdaqCIK 1607678Healthcare / Drug Manufacturersfiscal year ends December51 quarters since 2014
Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.
Share price
Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.
The last 16 quarters
Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.
Net income losses drawn in red.
Positions at each quarter end, as filed; short-term investments are not included.
Income statement
Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Oct 29, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026 | Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Cost of revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 167 | 116 | 150 | 153 | 90 | 60 | 41 | 31 | +85.4% |
| Selling, general and administrative | 20 | 17 | 14 | 11 | 9 | 14 | 14 | 15 | +135.9% |
| Operating income | (187) | (133) | (164) | (165) | (99) | (75) | (55) | (46) | −89.8% |
| Other income (expense) | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | −49.5% |
| Pretax income | — | — | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Net income | (183) | (128) | (158) | (158) | (91) | (66) | (46) | (35) | −101.8% |
| Diluted EPS ($) | (1.55) | (1.10) | (1.37) | — | (0.81) | (0.58) | (0.41) | — | −91.4% |
| Diluted shares (millions) | 118 | 116 | 116 | — | 112 | 112 | 112 | — | — |
Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.
Balance sheet
Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Oct 29, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026 | Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 678 | 126 | 118 | 166 | 100 | 34 | 38 | 27 | +575.1% |
| Short-term investments | 282 | 376 | 485 | 540 | 614 | 774 | 814 | 876 | −54.1% |
| Total current assets | 973 | 518 | 608 | 716 | 739 | 827 | 866 | 907 | +31.7% |
| Total assets | 977 | 522 | 608 | 716 | 739 | 828 | 867 | 908 | +32.2% |
| Total current liabilities | 134 | 110 | 106 | 77 | 26 | 32 | 20 | 27 | +413.7% |
| Long-term debt | — | — | — | — | — | — | — | — | — |
| Total debt | — | — | — | — | — | — | — | — | — |
| Total liabilities | 389 | 114 | 106 | 77 | 26 | 32 | 20 | 28 | +1372.7% |
| Stockholders’ equity | 589 | 408 | 502 | 639 | 713 | 795 | 847 | 880 | −17.5% |
| Shares outstanding (millions) | 128 | 117 | 116 | 116 | 113 | 112 | 112 | 112 | — |
Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.
Cash flow statement
Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.
| Millions of dollars | Q3 FY2026ended Sep 30, 2026filed Oct 29, 2026 | Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026 | Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026 | Q4 FY2025ended Dec 31, 2025filed Feb 11, 2026 | Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025 | Q2 FY2025ended Jun 30, 2025filed Jul 23, 2025 | Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025 | Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (138) | (125) | (114) | (85) | (94) | (47) | (52) | (31) | −47.0% |
| Capital expenditures | — | — | — | — | — | — | — | — | — |
| Free cash flow (CFO − capex) | — | — | — | — | — | — | — | — | — |
| Depreciation and amortization | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.
Annual statements
Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.
Income statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 11, 2026 | FY2024ended Dec 31, 2024filed Feb 26, 2025 | FY2023ended Dec 31, 2023filed Feb 7, 2024 | FY2022ended Dec 31, 2022filed Feb 10, 2023 | FY2021ended Dec 31, 2021filed Feb 9, 2022 | FY2020ended Dec 31, 2020filed Feb 17, 2021 | FY2019ended Dec 31, 2019filed Feb 26, 2020 | FY2018ended Dec 31, 2018filed Mar 13, 2019 | FY2017ended Dec 31, 2017filed Mar 7, 2018 | FY2016ended Dec 31, 2016filed Mar 21, 2017 | FY2015ended Dec 31, 2015filed Mar 8, 2016 | FY2014ended Dec 31, 2014filed Jun 12, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — |
| Research and development | 345 | 102 | 64 | 54 | 45 | 32 | 24 | 19 | 14 | 9 | 7 | 22 |
| Selling, general and administrative | 48 | 49 | 37 | 16 | 11 | 11 | 9 | 7 | 5 | 5 | 5 | 1 |
| Operating income | (393) | (151) | (101) | (70) | (56) | (43) | (33) | (26) | (19) | (14) | (12) | (23) |
| Other income (expense) | 34 | 41 | 15 | 1 | 1 | 3 | 7 | 4 | (2) | (1) | (11) | 2 |
| Pretax income | (360) | (110) | (86) | — | — | — | — | — | — | — | — | — |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Net income | (360) | (110) | (86) | (69) | (55) | (39) | (26) | (22) | (21) | (15) | (23) | (22) |
| Diluted EPS ($) | (3.19) | (1.01) | (0.91) | (0.90) | (0.71) | — | — | — | — | — | — | — |
| Diluted shares (millions) | 113 | 109 | 94 | 77 | 77 | — | — | — | — | — | — | — |
Balance sheet
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 11, 2026 | FY2024ended Dec 31, 2024filed Feb 26, 2025 | FY2023ended Dec 31, 2023filed Feb 7, 2024 | FY2022ended Dec 31, 2022filed Feb 10, 2023 | FY2021ended Dec 31, 2021filed Feb 9, 2022 | FY2020ended Dec 31, 2020filed Feb 17, 2021 | FY2019ended Dec 31, 2019filed Feb 26, 2020 | FY2018ended Dec 31, 2018filed Mar 13, 2019 | FY2017ended Dec 31, 2017filed Mar 7, 2018 | FY2016ended Dec 31, 2016filed Mar 21, 2017 | FY2015ended Dec 31, 2015filed Mar 8, 2016 | FY2014ended Dec 31, 2014filed Jun 12, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 166 | 27 | 56 | 37 | 26 | 29 | 8 | 25 | 9 | 3 | 1 | 1 |
| Short-term investments | 540 | 876 | 307 | 119 | 176 | 219 | 267 | 277 | 12 | — | — | — |
| Total current assets | 716 | 907 | 367 | 167 | 211 | 256 | 284 | 302 | 22 | 14 | 15 | 1 |
| Total assets | 716 | 908 | 368 | 169 | 211 | 257 | 284 | 302 | 22 | 15 | 15 | 3 |
| Total current liabilities | 77 | 27 | 19 | 22 | 9 | 12 | 7 | 5 | 9 | 6 | 2 | 23 |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — |
| Total debt | — | — | — | — | — | — | — | — | — | — | — | — |
| Total liabilities | 77 | 28 | 20 | 23 | 9 | 12 | 7 | 5 | 9 | 6 | 7 | 25 |
| Stockholders’ equity | 639 | 880 | 348 | 145 | 202 | 244 | 277 | 298 | 13 | 8 | 9 | (22) |
| Shares outstanding (millions) | 116 | 112 | 100 | 78 | 78 | 74 | 73 | 72 | 51 | 24 | 10 | — |
Cash flow statement
| Millions of dollars | FY2025ended Dec 31, 2025filed Feb 11, 2026 | FY2024ended Dec 31, 2024filed Feb 26, 2025 | FY2023ended Dec 31, 2023filed Feb 7, 2024 | FY2022ended Dec 31, 2022filed Feb 10, 2023 | FY2021ended Dec 31, 2021filed Feb 9, 2022 | FY2020ended Dec 31, 2020filed Feb 17, 2021 | FY2019ended Dec 31, 2019filed Feb 26, 2020 | FY2018ended Dec 31, 2018filed Mar 13, 2019 | FY2017ended Dec 31, 2017filed Mar 7, 2018 | FY2016ended Dec 31, 2016filed Mar 21, 2017 | FY2015ended Dec 31, 2015filed Mar 8, 2016 | FY2014ended Dec 31, 2014filed Jun 12, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (279) | (88) | (73) | (48) | (48) | (22) | (25) | (19) | (15) | — | — | — |
| Capital expenditures | — | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow (CFO − capex) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | 7 | — | — | — | — | — | 0 | 0 | 0 |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — |
Insider activity
Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.
The last 25 transactions
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | Director | award | 6,333 | $0.00 | — | 6,333 | Aug 7, 2026 |
| Jul 29, 2026 | Lian Brian | President & CEO, Director | open-market sale | 148,517 | $33.32 | $5M | 3M | Jul 29, 2026 |
| Jul 29, 2026 | Zante Greg | Chief Financial Officer | open-market sale | 21,217 | $33.47 | $710K | 212,204 | Jul 29, 2026 |
| Jul 29, 2026 | Mancini Marianna | Chief Operating Officer | open-market sale | 18,217 | $33.47 | $610K | 422,760 | Jul 29, 2026 |
| Jul 28, 2026 | Lian Brian | President & CEO, Director | award | 221,667 | $0.00 | — | 3M | Jul 29, 2026 |
| Jul 28, 2026 | Zante Greg | Chief Financial Officer | award | 31,667 | $0.00 | — | 233,421 | Jul 29, 2026 |
| Jul 28, 2026 | Mancini Marianna | Chief Operating Officer | award | 31,667 | $0.00 | — | 440,977 | Jul 29, 2026 |
| Mar 10, 2026 | Aubuchon Neil William | Chief Commercial Officer | open-market buy | 4,475 | $33.50 | $150K | 4,475 | Mar 10, 2026 |
| Jan 5, 2026 | Zante Greg | Chief Financial Officer | open-market sale | 31,961 | $32.30 | $1M | 215,571 | Jan 5, 2026 |
| Jan 5, 2026 | Zante Greg | Chief Financial Officer | open-market sale | 13,900 | $33.38 | $464K | 201,671 | Jan 5, 2026 |
| Jan 5, 2026 | Zante Greg | Chief Financial Officer | open-market sale | 10,300 | $34.24 | $353K | 191,371 | Jan 5, 2026 |
| Jan 5, 2026 | Zante Greg | Chief Financial Officer | open-market sale | 1,500 | $32.09 | $48K | 189,891 | Jan 5, 2026 |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | open-market sale | 31,961 | $32.29 | $1M | 434,890 | Jan 5, 2026 |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | open-market sale | 13,600 | $33.37 | $454K | 421,290 | Jan 5, 2026 |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | open-market sale | 10,500 | $34.22 | $359K | 410,790 | Jan 5, 2026 |
| Jan 5, 2026 | Mancini Marianna | Chief Operating Officer | open-market sale | 1,600 | $35.07 | $56K | 409,190 | Jan 5, 2026 |
| Jan 5, 2026 | Lian Brian | President & CEO, Director | open-market sale | 6,400 | $35.07 | $224K | 2M | Jan 5, 2026 |
| Jan 5, 2026 | Lian Brian | President & CEO, Director | open-market sale | 53,279 | $33.38 | $2M | 3M | Jan 5, 2026 |
| Jan 5, 2026 | Lian Brian | President & CEO, Director | open-market sale | 41,276 | $34.22 | $1M | 3M | Jan 5, 2026 |
| Jan 5, 2026 | Lian Brian | President & CEO, Director | open-market sale | 132,454 | $32.29 | $4M | 3M | Jan 5, 2026 |
| Jan 2, 2026 | Zante Greg | Chief Financial Officer | award | 41,000 | $0.00 | — | 215,483 | Jan 5, 2026 |
| Jan 2, 2026 | Zante Greg | Chief Financial Officer | award | 32,049 | $0.00 | — | 247,532 | Jan 5, 2026 |
| Jan 2, 2026 | Mancini Marianna | Chief Operating Officer | award | 41,000 | $0.00 | — | 434,802 | Jan 5, 2026 |
| Jan 2, 2026 | Mancini Marianna | Chief Operating Officer | award | 32,049 | $0.00 | — | 466,851 | Jan 5, 2026 |
| Jan 2, 2026 | Lian Brian | President & CEO, Director | award | 224,080 | $0.00 | — | 3M | Jan 5, 2026 |
Full insider history for Viking Therapeutics, Inc, or insider activity across all companies. A record of filings, not a recommendation.
Sources
Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.
- Filer
- VIKING THERAPEUTICS, INC., CIK 1607678 on EDGAR
- Extract generated
- November 16, 2026
- Withheld
- none
- Repaired
- 1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: net income FY2014
XBRL concepts behind each line
Income statement
RevenueFromContractWithCustomerExcludingAssessedTax, RevenuesResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseOperatingIncomeLossOtherNonoperatingIncomeExpenseIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncomeTaxExpenseBenefitNetIncomeLossEarningsPerShareDilutedWeightedAverageNumberOfDilutedSharesOutstandingBalance sheet
CashAndCashEquivalentsAtCarryingValueAvailableForSaleSecuritiesDebtSecuritiesCurrentAssetsCurrentAssetsLiabilitiesCurrentLiabilitiesStockholdersEquitydei:EntityCommonStockSharesOutstandingCash flow statement
NetCashProvidedByUsedInOperatingActivitiesPaymentsForRepurchaseOfCommonStockThe data
The statements on this page as files, generated November 16, 2026.
- JSON file
/data/financials/VKTX.json